Join us this month as we promote awareness for women’s eye health. Let’s prioritize vision wellness and safety practices for all women. #WomensEyeHealthMonth #EyeHealth #VisionCare

Ocugen announced the dosing completion for subjects with geographic atrophy in Cohort 2 (medium dose) of the Phase 1/2 ArMaDa clinical trial of OCU410. Geographic atrophy affects approximately 1 million people in the US alone. Full press release here: bitly.ws/3ikDI

The month of May marks Healthy Vision Month, a time to prioritize our eye health and raise awareness about the importance of regular check-ups and preventive measures. Let's commit to clearer, brighter futures by taking care of our vision today. #HealthyVisionMonth #EyeHealth

Join us in celebrating Asian American and Pacific Islander Month! Let’s honor the vibrant culture, history, and invaluable contributions of the Asian American and Pacific Islander community. #AAPIHeritageMonth #CelebrateDiversity

This Memorial Day we honor and remember those who have made the ultimate sacrifice for our freedom. Let’s take a moment to reflect on their contributions and express our gratitude. Thank you to all those who serve our country! #MemorialDay

Today Ocugen announced that the Data and Safety Monitoring Board approved enrollment in Cohort 3 as well as Phase 2 initiation in the OCU410 ArMaDa Study for Geographic Atrophy. Read the full press release here: bit.ly/4aLjz6H

Marking the 40th year of Deafblind Awareness Week, let's celebrate the strength, resilience, and incredible abilities of the Deafblind community. Together, we can foster an environment where everyone can thrive. #DeafblindAwarenessWeek

Reflecting on the spirit of Independence Day this Fourth of July. Wishing everyone a safe and celebratory day! #FourthofJuly #IndependenceDay

Your vision matters! Join us in observing Eye Injury Prevention Month by wearing protective eyewear and prioritizing eye safety. #EyeInjuryPreventionMonth

Hear from a patient with retinitis pigmentosa (RP) who participated in the OCU400 Phase 1/2 clinical trial. RP is a group of rare, genetic disorders that involve a breakdown and loss of cells in the retina, leading to vision loss and blindness. #RetinitisPigmentosa #IRD

This preclinical pharmacological study performed by Dr. Neena Haider’s team evaluated the effect of NR2E3 gene therapy in the rd7 animal model of retinal degeneration at various doses in early and intermediate stages of the disease. nature.com/articles/s4159…. #RP #GeneTherapy

Today, Dr. Benjamin Bakall, MD, PhD presented a late breaking abstract titled, “One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa” during the ASRS Annual meeting in Stockholm, Sweden.

Keep your eyes safe this summer! Protect your eyes from harmful UV rays by wearing sunglasses and hats when outdoors! #UVEyeSafetyMonth #LoveYourEyes

Listen as Dr. David Birch, PhD., Scientific Director at Retina Foundation of the Southwest discusses the complexities of retinitis pigmentosa and its devastating impact on patients.

Dosing is complete in the third cohort of the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). For more information, read the full press release here: shorturl.at/nM0rf

Ocugen announced that they have received notification from FDA to begin its EAP for the treatment of patients, aged 18 and older, with retinitis pigmentosa with OCU400. This is the first U.S. FDA-approved therapy to treat patients with RP. Read the PR: bit.ly/4d9CIRB

Protecting small eyes for brighter futures! August is Children’s Eye Health and Safety Month. Let’s ensure our children have clear and healthy vision! #ChildrenEyeHealth #EyeSafety

Today, Ocugen announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT clinical trial. Clinical sites in Canada may expedite recruitment and open doors for broader commercialization with the U.S. and Europe. bit.ly/3AE1kUl

Today, Ocugen announced the completion of dosing subjects in the high dose cohort of Phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate being developed for Stargardt disease. Read the full press release here: bit.ly/3Xn689F #genetherapy

Ocugen CMO, Dr. Huma Qamar’s, most recent article “A Vision for Inclusion: Designing Trials That Benefit Visually Impaired Patients” has been published in Clinical Leader. Read the full article here: bit.ly/4cS6clX